^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1d
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=46, Recruiting, AstraZeneca | N=162 --> 46 | Trial completion date: Aug 2039 --> Jul 2029
    Enrollment change • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    3d
    CAR T Cell Immunotherapy for Pancreatic Cancer (clinicaltrials.gov)
    P1, N=54, Terminated, University of Pennsylvania | N=18 --> 54 | Trial completion date: Dec 2025 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Feb 2025; Administrative reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    3d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    4d
    Research on Disease-Specific Exosome Detection Technologies and Prototype Development (Common Key Technologies) (ChiCTR2600116298)
    P=N/A, N=0, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial
    4d
    Clinical application of FL-091 radionuclide imaging in diagnosis and staging of malignant tumors (ChiCTR2500113089)
    P=N/A, N=0, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    4d
    Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (ChiCTR2500114031)
    P2, N=156, Not yet recruiting, Peking University Cancer Hospital & Institute; Peking University Cancer Hospital & Institute
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab)
    4d
    Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study (SCART-P) (ChiCTR2500111705)
    P1, N=24, Not yet recruiting, Affiliated Cancer Hospital of Shandong First Medical University; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong
    New P1 trial
    4d
    Gasdermin E-mediated lysosome-pore formation curbs pancreatic ductal adenocarcinoma via IFN-γ/IFN-β/TGF-β cocktail mRNA-LNP. (PubMed, Cell Mol Immunol)
    In parallel, IFN-β activates STAT1/STAT3 to upregulate cathepsin D expression, whereas TGF-β enhances GSDME phosphorylation by downregulating PPP1R3G, a regulatory subunit of protein phosphatase 1. Using lipid-hybrid nanoparticle-delivered mRNA technology, the tri-cytokine cocktail demonstrated therapeutic efficacy against orthotopic PDAC in mice and PDX models, highlighting its translational potential for PDAC patients.
    Journal
    |
    IFNG (Interferon, gamma) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CTSD (Cathepsin D) • GSDME (Gasdermin E) • IFNB1 (Interferon Beta 1)
    4d
    Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. (PubMed, J Immunother Cancer)
    REVOLUTION cohorts A and B demonstrated encouraging antitumor activity in patients with mPDAC. In cohort B, hydroxychloroquine-related tolerability issues contributed to early discontinuations and reduced drug exposure. These findings highlight the potential and limitations of current chemoimmunotherapy approaches. Although neither cohort will be expanded, the results reinforce the continued promise of chemoimmunotherapy in mPDAC and the importance of refining these strategies.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • albumin-bound paclitaxel • hydroxychloroquine
    4d
    ADGRG6 Promotes Pancreatic Adenocarcinoma Progression Through the NF-κB/STAT6 Axis and Modulation of the Tumor Immune Microenvironment. (PubMed, Curr Issues Mol Biol)
    ADGRG6 functions as an oncogenic driver in PAAD, promoting tumor progression and fostering an immunosuppressive microenvironment via NF-κB/STAT6 signaling. These findings not only broaden the mechanistic understanding of ADGRG6 function but also suggest it as a promising target for therapeutic intervention in PAAD.
    Journal
    |
    STAT6 (Signal transducer and activator of transcription 6) • ADGRG6 (Adhesion G Protein-Coupled Receptor G6) • GATA3 (GATA binding protein 3)
    5d
    Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors. (PubMed, Clin Epigenetics)
    This study uncovers DNA methylation subtypes within resistant tumors, enabling more precise stratification to inform prognosis and therapy selection.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    gemcitabine • temozolomide